Traws Pharma (TRAW)
NASDAQ:TRAW
Want to see TRAW full AI Analyst Report?
TRAW Stock Chart & Stats
$1.25
-$0.87(-9.63%)
At close: 4:00 PM EST
$1.25
-$0.87(-9.63%)
Day’s Range― - ―
52-Week Range$0.64 - $3.27
Previous CloseN/A
Volume35.69K
Average Volume (3M)206.36K
Market Cap
$11.45M
Enterprise Value$4.51M
Total Cash (Recent Filing)$3.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Aug 06, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding15,150,669
10 Day Avg. Volume403,079
30 Day Avg. Volume206,356
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue1.65
Enterprise Value/Gross Profit1.65
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$8.00Price Target Upside540.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Broad‑spectrum Antiviral Platform & Global PartnershipsTraws is building a host‑targeted, broad‑spectrum antiviral program and formalizing regulatory and manufacturing partnerships across the U.S., Africa and global agencies. Those structural collaborations and local manufacturing plans support scalable outbreak response, improved access, and durable market positioning in pandemic preparedness.
Secured Milestone‑linked PIPE Financing Extending RunwayThe PIPE and ATM provisions provide tangible near‑term liquidity and tie most follow‑on capital to clinical and regulatory milestones. Combined with reported absence of debt, this financing structure reduces immediate solvency pressure and gives the company time to advance key trials and de‑risk programs before requiring large, unconditional equity raises.
Proof‑of‑concept Phase 2a Data For RatutrelvirPositive clinical POC for ratutrelvir materially de‑risks one of Traws' lead assets, supporting progression to larger trials or partnering. Durable clinical validation improves the company's ability to attract collaborators, regulatory engagement and potential stockpiling or commercial interest in antiviral markets beyond one‑off pandemic cycles.
Bears Say
Regulatory Setback: Deferred Phase 2a Influenza StudyThe MHRA review and subsequent deferral create structural execution risk for the tivoxavir program, likely lengthening timelines and requiring additional data or design changes. This setback can delay regulatory milestones that trigger financing tranches and commercial timelines, reducing near‑term optionality for the lead influenza asset.
Consistent Negative Operating Cash Flow And High Cash BurnPersistent negative operating cash flow and a sharp 2025 cash burn show the business is not self‑funding and reliant on external capital. With runway only extended to Q1 2027 by milestone‑linked financing, ongoing burn raises dilution risk and constrains strategic optionality for multi‑year clinical development plans.
Negative Equity And Low Earnings QualityNegative shareholders' equity signals cumulative losses or write‑downs that weaken the capital base and may impair future financing terms. The 2025 profit and revenue spike appears driven by non‑operating items, indicating earnings quality issues and that sustainable operating profitability has not been established, increasing long‑term solvency risk.
Traws Pharma News
TRAW FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was $0.64 and its highest was $3.27 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is $11.45M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is Aug 06, 2026 which is in 50 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on May 15, 2026. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.56 by $0.03.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Undervalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -0.43.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 15,150,669 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.56. Following the earnings report the stock price went up 15.337%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in TRAW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Traws Pharma
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
TRAW Stock 12 Month Forecast
Average Price Target
$8.00
▲(540.00% Upside)
Technical Analysis
Ownership Overview
12.55% Insiders
0.74% Mutual Funds
20.94% Other Institutional Investors
65.40% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---